Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Medical therapy
Phytotherapy
Progression
Prostatic hyperplasia
Prostatic inflammation
Serenoa repens
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
10
12
2019
accepted:
23
01
2020
pubmed:
16
2
2020
medline:
22
6
2021
entrez:
16
2
2020
Statut:
ppublish
Résumé
To review the role of a persistent prostatic inflammatory status (PIS) in the development and progression of benign prostatic hyperplasia (BPH) associated with lower urinary tract symptoms (LUTS) and which medical therapies approved for LUTS/BPH may reduce persistent PIS. Literature search in PubMed up to July 2019. The cause of histologically defined persistent PIS or chronic prostatic inflammation is multifactorial. It is evident in many men with LUTS/BPH, particularly in older men and in men with a large prostate volume or more severe (storage) LUTS. Additionally, persistent PIS is associated with an increased risk of acute urinary retention and symptom worsening. Of medical therapies approved for LUTS/BPH, the current evidence for a reduction of persistent PIS is greatest for the hexanic extract of Serenoa repens (HESr). This treatment relieves LUTS to the same extent as α Persistent PIS plays a central role in both the development and progression of LUTS/BPH. In men with LUTS/BPH who have a high chance of harbouring persistent PIS, HESr will not only improve LUTS, but also reduce (underlying) inflammation. Well-designed clinical studies, with a good level of evidence, are required to better evaluate the impact of BPH/LUTS medical therapies on persistent PIS.
Identifiants
pubmed: 32060633
doi: 10.1007/s00345-020-03106-1
pii: 10.1007/s00345-020-03106-1
pmc: PMC7644532
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2771-2779Commentaires et corrections
Type : ErratumIn
Références
Berry SJ, Coffey DS, Walsh PC, Ewing LJ (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479. https://doi.org/10.1016/S0022-5347%2817%2949698-4
doi: 10.1016/S0022-5347%2817%2949698-4
Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, Rieken M, Speakman MJ, Tikkinen KAO (2019) Management of non-neurogenic male LUTS. EAU guidelines 2019. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#1 . Accessed Aug 2019
He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S (2016) Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis 19:7–13. https://doi.org/10.1038/pcan.2015.43
doi: 10.1038/pcan.2015.43
De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, Sciarra A, Tubaro A (2011) The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 60:106–117. https://doi.org/10.1016/j.eururo.2011.03.055
doi: 10.1016/j.eururo.2011.03.055
De Nunzio C, Presicce F, Tubaro A (2016) Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol 13:613–626. https://doi.org/10.1038/nrurol.2016.168
doi: 10.1038/nrurol.2016.168
Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B (2013) Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol 23:5–10. https://doi.org/10.1097/MOU.0b013e32835abd4a
doi: 10.1097/MOU.0b013e32835abd4a
Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F (2013) The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 112:432–441. https://doi.org/10.1111/bju.12118
doi: 10.1111/bju.12118
Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, Mirone V, Scaglione F (2014) The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep 15:463. https://doi.org/10.1007/s11934-014-0463-9
doi: 10.1007/s11934-014-0463-9
Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J (1997) Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 157:1301–1303. https://doi.org/10.1016/S0022-5347%2801%2964957-7
doi: 10.1016/S0022-5347%2801%2964957-7
Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A (2003) Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 43:164–175. https://doi.org/10.1016/S0302-2838(02)00548-1
doi: 10.1016/S0302-2838(02)00548-1
Roehrborn C et al (2005) The impact of acute and chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. J Urol 173(Suppl):346 (abstract 1277)
doi: 10.1016/S0022-5347(18)35422-3
Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS (2008) The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 54:1379–1384. https://doi.org/10.1016/j.eururo.2007.11.026
doi: 10.1016/j.eururo.2007.11.026
Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, Takahashi H, Kuk C, Kovylina M, Aldaoud N, Fleshner N, Finelli A, Klotz L, Lockwood G, Sykes J, van der Kwast T (2014) Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol 66:619–622. https://doi.org/10.1016/j.eururo.2014.06.026
doi: 10.1016/j.eururo.2014.06.026
Robert G, Descazeaud A, Allory Y, Vacherot F, de la Taille A (2009) Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol Suppl 8:879–886. https://doi.org/10.1016/j.eursup.2009.11.004
doi: 10.1016/j.eursup.2009.11.004
Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, de la Taille A (2009) Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 69:1774–1780. https://doi.org/10.1002/pros.21027
doi: 10.1002/pros.21027
Kim SH, Jung KI, Koh JS, Min KO, Cho SY, Kim HW (2013) Lower urinary tract symptoms in benign prostatic hyperplasia patients: orchestrated by chronic prostatic inflammation and prostatic calculi? Urol Int 90:144–149. https://doi.org/10.1159/000342643
doi: 10.1159/000342643
Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, Moreira DM (2016) Chronic prostate inflammation is associated with severity and progression of benign prostatic hyperplasia, lower urinary tract symptoms and risk of acute urinary retention. J Urol 196:1493–1498. https://doi.org/10.1016/j.juro.2016.06.090
doi: 10.1016/j.juro.2016.06.090
Tuncel A, Uzun B, Eruyar T, Karabulut E, Seckin S, Atan A (2005) Do prostatic infarction, prostatic inflammation and prostate morphology play a role in acute urinary retention? Eur Urol 48:277–284. https://doi.org/10.1016/j.eururo.2005.05.001
doi: 10.1016/j.eururo.2005.05.001
Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM, Motiwala HG, Laniado ME (2007) Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 100:327–331. https://doi.org/10.1111/j.1464-410X.2007.06910.x
doi: 10.1111/j.1464-410X.2007.06910.x
van Vuuren SPJ, Heyns CF, Zarrabi AD (2012) Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate. BJU Int 109:1194–1197. https://doi.org/10.1111/j.1464-410X.2011.10527.x
doi: 10.1111/j.1464-410X.2011.10527.x
Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS (2007) Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol 178(3(Pt 1)):896–901. https://doi.org/10.1016/j.juro.2007.05.041
doi: 10.1016/j.juro.2007.05.041
Ficarra V (2013) Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)? BJU Int 12:421–422. https://doi.org/10.1111/bju.12177
doi: 10.1111/bju.12177
Bardan R, Dumache R, Dema A, Cumpanas A, Bucuras V (2014) The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases. Clin Biochem 47(10–11):909–915. https://doi.org/10.1016/j.clinbiochem.2014.02.008
doi: 10.1016/j.clinbiochem.2014.02.008
Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, Fibbi B, Colli E, Maggi M, Adorini L (2007) Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 51:524–533. https://doi.org/10.1016/j.eururo.2006.07.016
doi: 10.1016/j.eururo.2006.07.016
Lotti F, Maggi M (2013) Interleukin 8 and the male genital tract. J Reprod Immunol 100:54–65. https://doi.org/10.1016/j.jri.2013.02.004
doi: 10.1016/j.jri.2013.02.004
Liu L, Li Q, Han P, Li X, Zeng H, Zhu Y, Wei Q (2009) Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia. Urology 74:340–344. https://doi.org/10.1016/j.urology.2009.02.064
doi: 10.1016/j.urology.2009.02.064
Novara G, Giannarini G, Alcaraz A, Cózar-Olmo JM, Descazeaud A, Montorsi F, Ficarra V (2016) Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. Eur Urol Focus 2:553–561. https://doi.org/10.1016/j.euf.2016.04.002
doi: 10.1016/j.euf.2016.04.002
Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, Miñana López B, Fernández-Gómez JM, Angulo JC, Castro Díaz D, Romero-Otero J, Brenes FJ, Carballido J, Molero García JM, Fernández-Pro Ledesma A, Cózar Olmos JM, Manasanch Dalmau J, Subirana Cachinero I, Herdman M, Ficarra V (2018) Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
doi: 10.1111/bju.14362
Scaglione F (2015) How to choose the right Serenoa repens extract. Eur Urol Suppl 14:e1464–e1469. https://doi.org/10.1016/S1569-9056(15)30501-7
doi: 10.1016/S1569-9056(15)30501-7
Marti G, Joulia P, Amiel A, Fabre B, David B, Fabre N, Fiorini-Puybaret C (2019) Comparison of the phytochemical composition of serenoa repens extracts by a multiplexed metabolomic approach. Molecules 24(12):2208. https://doi.org/10.3390/molecules24122208
doi: 10.3390/molecules24122208
Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ (2012) Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 12:Cd001423. https://doi.org/10.1002/14651858.CD001423.pub3
doi: 10.1002/14651858.CD001423.pub3
European Medicines Agency (2015) Assessment report on Serenoa repens (W. Bartram) Small, fructus. Final, 24 November 2015. https://www.ema.europa.eu/en/medicines/herbal/sabalis-serrulatae-fructus . Accessed Aug 2019.
Funahashi Y, Majima T, Matsukawa Y, Yamamoto T, Yoshida M, Gotoh M (2017) Intraprostatic reflux of urine induces inflammation in a rat. Prostate 77:164–172. https://doi.org/10.1002/pros.23257
doi: 10.1002/pros.23257
Seo SI, Lee SJ, Kim JC, Choi YJ, Kim SW, Hwang TK, Cho YH (2003) Effects of androgen deprivation on chronic bacterial prostatitis in a rat model. Int J Urol 10:485–491. https://doi.org/10.1046/j.1442-2042.2003.00666.x
doi: 10.1046/j.1442-2042.2003.00666.x
Tsujimura A, Fukuhara S, Soda T, Takezawa K, Kiuchi H, Takao T, Miyagawa Y, Nonomura N, Adachi S, Tokita Y, Nomura T (2015) Histologic evaluation of human benign prostatic hyperplasia treated by dutasteride: a study by xenograft model with improved severe combined immunodeficient mice. Urology 85:e271–e278. https://doi.org/10.1016/j.urology.2014.09.024
doi: 10.1016/j.urology.2014.09.024
Pigat N, Reyes-Gomez E, Boutillon F, Palea S, Barry Delongchamps N, Koch E, Goffin V (2019) Combined sabal and urtica extracts (WS
doi: 10.3389/fphar.2019.00311
Park DS, Shim JY (2008) Histologic influence of doxazosin and finasteride in benign prostatic hyperplasia accompanying chronic inflammation. Urol Int 81:441–446. https://doi.org/10.1159/000167844
doi: 10.1159/000167844
Kwon YK, Choe MS, Seo KW, Park CH, Chang HS, Kim BH, Kim CI (2010) The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment. Korean J Urol 51:266–270. https://doi.org/10.4111/kju.2010.51.4.266
doi: 10.4111/kju.2010.51.4.266
Lee HN, Kim TH, Lee SJ, Cho WY, Shim BS (2014) Effects of prostatic inflammation on LUTS and alpha blocker treatment outcomes. Int Braz J Urol 40:356–366. https://doi.org/10.1590/S1677-5538.IBJU.2014.03.09
doi: 10.1590/S1677-5538.IBJU.2014.03.09
Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V, Oelke M, Porst H, Roehrborn C, Stief C, Giuliano F (2016) Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 70:124–133. https://doi.org/10.1016/j.eururo.2015.12.048
doi: 10.1016/j.eururo.2015.12.048
Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, Cellai I, Gacci M, Lenzi A, Vannelli GB, Maggi M (2013) Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate 73:428–441. https://doi.org/10.1002/pros.22584
doi: 10.1002/pros.22584
Okamoto K, Kurita M, Yamaguchi H, Numakura Y, Oka M (2017) Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis. Prostate 78:707–713. https://doi.org/10.1002/pros.23514
doi: 10.1002/pros.23514
Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, Comeglio P, Santi R, Filippi S, Sebastianelli A, Nesi G, Serni S, Carini M, Maggi M (2013) PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 73:1391–1402. https://doi.org/10.1002/pros.22686
doi: 10.1002/pros.22686
Jin S, Xiang P, Liu J, Yang Y, Hu S, Sheng J, He Q, Yu W, Han W, Jin J, Peng J (2019) Activation of cGMP/PKG/p65 signaling associated with PDE5-Is downregulates CCL5 secretion by CD8
doi: 10.1002/pros.23801
Robert GY (2015) Comparison of the effects of the hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammatory biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl 14:e1470–e1474
doi: 10.1016/S1569-9056(15)30502-9
Vela Navarette R, Garcia Cardoso JV, Barat A, Manzarbeitia F, López Farré A (2003) BPH and inflammation: pharmacological effects of permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 44:549–555. https://doi.org/10.1016/s0302-2838(03)00368-3
doi: 10.1016/s0302-2838(03)00368-3
Bernichtein S, Pigat N, Camparo P, Latil A, Viltard M, Friedlander G, Goffin V (2015) Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixonα
doi: 10.1002/pros.22953
Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P (1997) Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon
doi: 10.1016/S0952-3278(97)90548-2
Bonvissuto G, Minutoli L, Morgia G, Bitto A, Polito F, Irrera N, Marini H, Squadrito F, Altavilla D (2011) Effect of Serenoa repens, lycopene, and selenium on proinflammatory phenotype activation: an in vitro and in vivo comparison study. Urology 77:e216–e249. https://doi.org/10.1016/j.urology.2010.07.514
doi: 10.1016/j.urology.2010.07.514
Latil A, Libon C, Templier M, Junquero D, Lantoine-Adam F, Nguyen T (2012) Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int 110(6 Pt B):E301–E307. https://doi.org/10.1111/j.1464-410X.2012.11144.x
doi: 10.1111/j.1464-410X.2012.11144.x
Colado-Velázquez J III, Mailloux-Salinas P, Medina-Contreras JML, Cruz-Robles D, Bravo G (2015) Effect of Serenoa repens on oxidative stress, inflammatory and growth factors in obese wistar rats with benign prostatic hyperplasia. Phytother Res 29:1525–1531. https://doi.org/10.1002/ptr.5406
doi: 10.1002/ptr.5406
Chiavaroli A, Recinella L, Ferrante C, Locatelli M, Carradori S, Macchione N, Zengin G, Leporini L, Leone S, Martinotti S, Brunetti L, Vacca M, Menghini L, Orlando G (2017) Crocus sativus, Serenoa repens and Pinus massoniana extracts modulate inflammatory response in isolated rat prostate challenged with LPS. J Biol Regul Homeost Agents 31:531–541
Sirab N, Robert G, Fasolo V, Descazeaud A, Vacherot F, de la Taille A, Terry S (2013) Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci 14:14301–14320. https://doi.org/10.3390/ijms140714301
doi: 10.3390/ijms140714301
Latil A, Pétrissans MT, Rouquet J, Robert G, de la Taille A (2015) Effects of hexanic extract of Serenoa repens (Permixon
doi: 10.1002/pros.23059
Gravas S, Samarinas M, Zacharouli K, Karatzas A, Tzortzis V, Koukoulis G, Melekos M (2019) The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study. World J Urol 37:539–544. https://doi.org/10.1007/s00345-018-2409-1
doi: 10.1007/s00345-018-2409-1
Alcaraz A, Carballido-Rodríguez J, Unda-Urzaiz M, Medina-López R, Ruiz-Cerdá JL, Rodríguez-Rubio F, García-Rojo D, Brenes-Bermúdez FJ, Cózar-Olmo JM, Baena-González V, Manasanch J (2016) Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study. Int Urol Nephrol 48:645–656. https://doi.org/10.1007/s11255-015-1206-7
doi: 10.1007/s11255-015-1206-7
Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Calais Da Silva F, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P (1996) Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate 29:231–240. https://doi.org/10.1002/(SICI)1097-0045(199610)29:4%3c231:AID-PROS4%3e3.0.CO;2-E
doi: 10.1002/(SICI)1097-0045(199610)29:4%3c231::AID-PROS4%3e3.0.CO;2-E
Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP (2002) Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 41:497–507
doi: 10.1016/S0302-2838(02)00066-0
Glemain P, Coulange C, Billebaud T, Gattegno B, Muszynski R, Loeb G (2002) Tamsulosine avec ou sans Serenoa repens dans l'hypertrophie bénigne de la prostate: l'essai OCOS [Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial]. Prog Urol 12:395–403
Ryu YW, Lim SW, Kim JH, Ahn SH, Choi JD (2015) Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urol Int 94:187–193. https://doi.org/10.1159/000366521
doi: 10.1159/000366521
Boeri L, Capogrosso P, Ventimiglia E, Cazzaniga W, Pederzoli F, Moretti D, Dehò F, Montanari E, Montorsi F, Salonia A (2017) Clinically meaningful improvements in LUTS/BPH severity in men treated with silodosin plus hexanic extract of Serenoa repens or silodosin alone. Sci Rep 7:15179. https://doi.org/10.1038/s41598-017-15435-0
doi: 10.1038/s41598-017-15435-0